Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Reports Adverse Effects from Vaccine Limited to One Case

publication date: Dec 2, 2008

Sinovac Biotech Ltd. (京科兴生物制品有限公司) released a statement clarifying the situation regarding the suspension of its most important product, the hepatitis A vaccine Healive®. The company said the Health Services Bureau of Fengtai District in Beijing suspended the use of just 83 doses of the drug. The action came after the death of a minor who had been treated with the vaccine two days previously. The company said no other adverse reactions have been reported thus far. More details...

Stock Symbol: (NYSE Alternext: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital